​

Amgen (AMGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AMGN Stock Forecast

Amgen stock forecast is as follows: an average price target of $338.22 (represents a 20.07% upside from AMGN’s last price of $281.68) and a rating consensus of 'Buy', based on 25 wall street analysts offering a 1-year stock forecast.

AMGN Price Target

The average price target for Amgen (AMGN) is $338.22 based on 1-year price targets from 25 Wall Street analysts in the past 3 months, with a price target range of $405.00 to $215.00. This represents a potential 20.07% upside from AMGN's last price of $281.68.

AMGN Analyst Ratings

Buy

According to 25 Wall Street analysts, Amgen's rating consensus is 'Buy'. The analyst rating breakdown for AMGN stock is 0 'Strong Buy' (0.00%), 15 'Buy' (60.00%), 8 'Hold' (32.00%), 2 'Sell' (8.00%), and 0 'Strong Sell' (0.00%).

Amgen Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 12, 2024Michael YeeJefferies$380.00$298.8427.16%34.90%
Nov 12, 2024Olivia BrayerCantor Fitzgerald$405.00$298.8435.52%43.78%
Oct 21, 2024Terence FlynnMorgan Stanley$319.00$316.740.71%13.25%
Oct 16, 2024Salveen RichterGoldman Sachs$369.00$325.0913.51%31.00%
Oct 07, 2024Carter GouldBarclays$315.00$319.66-1.46%11.83%
Sep 25, 2024Evan David SeigermanBMO Capital$362.00$330.929.39%28.51%
Sep 25, 2024Christopher RaymondRaymond James$344.00$330.923.95%22.12%
Sep 25, 2024Brian SkorneyRobert W. Baird$215.00$330.92-35.03%-23.67%
Aug 07, 2024Mohit BansalWells Fargo$335.00$328.951.84%18.93%
Aug 06, 2024Terence FlynnMorgan Stanley$303.00$330.79-8.40%7.57%
Jun 14, 2024Gregory RenzaRBC Capital$332.00$298.7111.14%17.86%
May 17, 2024Jay OlsonOppenheimer$380.00$312.3221.67%34.90%
May 09, 2024Salim SyedMizuho Securities$235.00$307.31-23.53%-16.57%
May 03, 2024Terence FlynnMorgan Stanley$310.00$315.19-1.65%10.05%
May 03, 2024Evan David SeigermanBMO Capital$355.00$278.3927.52%26.03%
May 03, 2024Colin BristowUBS$307.00$278.3910.28%8.99%
May 03, 2024Carter GouldBarclays$300.00$278.397.76%6.50%
Apr 17, 2024Mohit BansalWells Fargo$320.00$265.1120.71%13.60%
Sep 13, 2023Michael YeeJefferies$310.00$260.3119.09%10.05%
Sep 13, 2023Jay OlsonOppenheimer$280.00$260.317.56%-0.60%
Apr 12, 2023Mohit BansalWells Fargo$265.00$251.085.54%-5.92%
Mar 10, 2023Mohit BansalWells Fargo$275.00$228.8420.17%-2.37%
Feb 02, 2023Leerink Partners$267.00$246.418.36%-5.21%
Feb 01, 2023RBC Capital$258.00$242.926.21%-8.41%
Feb 01, 2023Oppenheimer$294.00$243.8020.59%4.37%
Feb 01, 2023Cowen & Co.$289.00$243.4718.70%2.60%
Feb 01, 2023BMO Capital$253.00$252.400.24%-10.18%
Jan 03, 2023Wells Fargo$285.00$260.679.33%1.18%
Dec 22, 2022Leerink Partners$282.00$266.265.91%0.11%
Dec 13, 2022Piper Sandler$299.00$276.788.03%6.15%
Dec 06, 2022Oppenheimer$310.00$285.598.55%10.05%
Dec 05, 2022Christopher RaymondRaymond James$297.00$285.733.95%5.44%
Nov 18, 2022Credit Suisse$240.00$287.30-16.46%-14.80%
Oct 31, 2022Carter GouldBarclays$234.00$273.81-14.54%-16.93%
Aug 09, 2022Atlantic Equities$182.00$247.29-26.40%-35.39%
Aug 05, 2022RBC Capital$236.00$246.98-4.45%-16.22%
Aug 05, 2022Piper Sandler$265.00$246.987.30%-5.92%
Jul 15, 2022Morgan Stanley$253.00$247.872.07%-10.18%
Jun 03, 2022Jay OlsonOppenheimer$290.00$248.9416.49%2.95%
May 10, 2022Salim SyedMizuho Securities$208.00$239.24-13.06%-26.16%
Apr 29, 2022Evan SeigermanBMO Capital$243.00$238.132.05%-13.73%
Apr 16, 2022Carter GouldBarclays$236.00$254.02-7.09%-16.22%
Feb 21, 2022Evan David SeigermanBMO Capital$240.00$220.778.71%-14.80%
Feb 08, 2022Christopher RaymondPiper Sandler$255.00$238.966.71%-9.47%
Feb 08, 2022Colin BristowUBS$232.00$238.96-2.91%-17.64%
Feb 08, 2022Kennen MacKayRBC Capital$218.00$238.96-8.77%-22.61%
Jan 27, 2022Yaron WerberCowen & Co.$275.00$222.1023.82%-2.37%
Jan 05, 2022Geoff MeachamBank of America Securities$255.00$223.2314.23%-9.47%
Dec 06, 2021Salveen RichterGoldman Sachs$258.00$207.0224.63%-8.41%
Nov 03, 2021Tim AndersonWolfe Research$230.00$214.477.24%-18.35%
Aug 05, 2021Elmar KrausDZ BANK AG$278.00$228.3121.76%-1.31%
Apr 28, 2021Tiago FauthCredit Suisse$259.00$229.3512.93%-8.05%
Apr 28, 2021Steve ChesneyAtlantic Equities$200.00$229.35-12.80%-29.00%

The latest Amgen stock forecast, released on Nov 12, 2024 by Michael Yee from Jefferies, set a price target of $380.00, which represents a 27.16% increase from the stock price at the time of the forecast ($298.84), and a 34.90% increase from AMGN last price ($281.68).

Amgen Price Target by Period

1M3M12M
# Anlaysts-218
Avg Price Target-$392.50$327.00
Last Closing Price$281.68$281.68$281.68
Upside/Downside-100.00%39.34%16.09%

In the current month, the average price target of Amgen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Amgen's last price of $281.68. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 27, 2024Cowen & Co.BuyBuyHold
Nov 13, 2024CitigroupNeutralInitialise
Nov 12, 2024BMO CapitalOutperformOutperformHold
Nov 12, 2024BarclaysNegativeNegativeHold
Nov 12, 2024JefferiesBuyBuyHold
Nov 12, 2024Cantor FitzgeraldOverweightOverweightHold
Oct 22, 2024Wells FargoBuyBuyHold
Oct 21, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Oct 21, 2024Cowen & Co.BuyBuyHold
Oct 17, 2024BernsteinOutperformInitialise
Oct 16, 2024Goldman SachsConviction BuyConviction BuyHold
Oct 07, 2024BarclaysEqual-WeightEqual-WeightHold
Sep 27, 2024Cantor FitzgeraldOverweightInitialise
Sep 25, 2024Wells FargoBuyBuyHold
Sep 25, 2024Cowen & Co.BuyBuyHold
Sep 25, 2024BMO CapitalOutperformOutperformHold
Sep 25, 2024Piper SandlerOverweightOverweightHold
Aug 07, 2024OppenheimerOutperformOutperformHold
Aug 07, 2024William BlairOutperformOutperformHold
Aug 07, 2024Cowen & Co.BuyBuyHold
Aug 07, 2024Wells FargoOverweightEqual-WeightDowngrade
Aug 06, 2024Argus ResearchBuyBuyHold
Aug 06, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Aug 06, 2024BMO CapitalOutperformOutperformHold
Aug 06, 2024RBC CapitalOutperformOutperformHold
Jul 19, 2024JefferiesBuyBuyHold
Jul 12, 2024UBSNeutralNeutralHold
Jun 14, 2024UBSBuyBuyHold
Jun 14, 2024RBC CapitalOutperformOutperformHold
May 22, 2024Wells FargoOverweightOverweightHold
May 17, 2024OppenheimerOutperformOutperformHold
May 03, 2024Morgan StanleyEqual-WeightEqual-WeightHold
May 03, 2024BMO CapitalOutperformOutperformHold
May 03, 2024UBSNeutralNeutralHold
May 03, 2024William BlairOutperformUpgrade
May 03, 2024BarclaysUnderweightEqual-WeightUpgrade
Apr 17, 2024Wells FargoOverweightOverweightHold
Apr 17, 2024Cowen & Co.BuyBuyHold
Apr 03, 2024UBSBuyBuyHold
Mar 13, 2024RBC CapitalOutperformOutperformHold
Mar 01, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Feb 07, 2024BMO CapitalOutperformOutperformHold
Jan 29, 2024UBSSector PerformSector PerformHold
Dec 21, 2023DaiwaBuyUpgrade
Dec 19, 2023UBSSector PerformSector PerformHold
Dec 19, 2023BMO CapitalMarket PerformOutperformUpgrade
Dec 12, 2023RBC CapitalSector PerformOutperformUpgrade
Nov 01, 2023RBC CapitalSector PerformSector PerformHold
Nov 01, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Oct 11, 2023Leerink PartnersOutperformUpgrade
Sep 13, 2023OppenheimerOutperformOutperformHold
Sep 13, 2023JefferiesBuyBuyHold
Aug 28, 2023Wells FargoEqual-WeightEqual-WeightHold
Aug 04, 2023CFRABuyUpgrade
Jun 08, 2023SVB LeerinkMarket PerformMarket PerformHold
May 09, 2023Wells FargoOverweightOverweightHold
Mar 13, 2023Raymond JamesMarket OutperformMarket PerformDowngrade
Mar 13, 2023Wolfe ResearchPeer PerformDowngrade
Mar 13, 2023Credit SuisseUnderperformNeutralDowngrade
Mar 13, 2023Craig-HallumHoldDowngrade
Mar 13, 2023Wells FargoEqual-WeightOverweightUpgrade
Mar 10, 2023SVB LeerinkMarket PerformMarket PerformHold
Feb 02, 2023SVB LeerinkMarket PerformMarket PerformHold
Feb 01, 2023OppenheimerOutperformOutperformHold
Feb 01, 2023Cowen & Co.OutperformOutperformHold
Feb 01, 2023Credit SuisseUnderperformUnderperformHold
Feb 01, 2023BMO CapitalMarket PerformMarket PerformHold
Feb 01, 2023BarclaysUnderweightUnderweightHold
Jan 03, 2023Wells FargoEqual-WeightEqual-WeightHold
Dec 22, 2022SVB LeerinkMarket PerformMarket PerformHold
Dec 13, 2022Piper SandlerOverweightOverweightHold
Dec 06, 2022OppenheimerOutperformOutperformHold
Nov 18, 2022Credit SuisseUnderperformInitialise
Nov 04, 2022Piper SandlerOverweightOverweightHold
Oct 11, 2022Wells FargoOutperformOverweightUpgrade
Oct 11, 2022BMO CapitalMarket PerformOutperformUpgrade
Oct 11, 2022Morgan StanleyBuyOverweightUpgrade
Oct 11, 2022Morgan StanleyEqual-WeightBuyUpgrade
Sep 12, 2022Prescience PointBuyBuyHold
Sep 12, 2022Wells FargoOutperformOutperformHold
Aug 26, 2022Piper SandlerOverweightOverweightHold
Aug 09, 2022Atlantic EquitiesUnderweightUnderweightHold
Aug 05, 2022Piper SandlerOverweightOverweightHold
Jul 15, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Jun 01, 2022OppenheimerOutperformOutperformHold
May 24, 2022SVB LeerinkMarket PerformInitialise
May 09, 2022Mizuho SecuritiesNeutralNeutralHold
Apr 29, 2022BMO CapitalMarket PerformMarket PerformHold
Apr 28, 2022Piper SandlerOverweightOverweightHold
Apr 16, 2022BarclaysEqual-WeightEqual-WeightHold
Apr 06, 2021OppenheimerOutperformOutperformHold
Oct 26, 2020Morgan StanleyOverweightOverweightHold
Oct 26, 2020Raymond JamesMarket OutperformUpgrade

Amgen's last stock rating was published by Cowen & Co. on Nov 27, 2024. The company gave AMGN a "Buy" rating, the same as its previous rate.

Amgen Financial Forecast

Amgen Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$8.20B$6.90B$6.99B$6.11B$6.84B$6.65B$6.59B$6.24B$6.85B$6.71B$6.53B$5.90B$6.63B$6.42B$6.21B$6.16B$6.20B$5.74B
Avg Forecast$8.78B$8.58B$8.58B$8.01B$8.93B$8.75B$8.78B$8.23B$8.86B$8.50B$8.35B$7.45B$8.13B$6.93B$6.66B$6.15B$6.74B$6.56B$6.53B$6.07B$6.87B$6.67B$6.46B$6.26B$6.57B$6.39B$6.19B$6.00B$6.03B$5.63B
High Forecast$9.39B$9.18B$9.18B$8.57B$9.55B$9.36B$9.39B$8.86B$9.15B$8.50B$8.35B$7.45B$8.30B$8.33B$7.13B$6.58B$7.04B$6.56B$6.53B$6.07B$6.87B$6.67B$6.46B$6.26B$6.57B$6.39B$6.19B$6.00B$6.03B$5.63B
Low Forecast$8.35B$8.17B$8.17B$7.62B$8.50B$8.33B$8.36B$7.89B$8.57B$8.50B$8.35B$7.45B$7.98B$6.73B$6.34B$5.86B$6.45B$6.56B$6.53B$6.07B$6.87B$6.67B$6.46B$6.26B$6.57B$6.39B$6.19B$6.00B$6.03B$5.63B
# Analysts33454527168991018159101681099139910101099
Surprise %------------1.01%1.00%1.05%0.99%1.01%1.01%1.01%1.03%1.00%1.01%1.01%0.94%1.01%1.01%1.00%1.03%1.03%1.02%

Amgen's average Quarter revenue forecast for Mar 24 based on 9 analysts is $7.45B, with a low forecast of $7.45B, and a high forecast of $7.45B. AMGN's average Quarter revenue forecast represents a -9.08% decrease compared to the company's last Quarter revenue of $8.20B (Dec 23).

Amgen EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527168991018159101681099139910101099
EBITDA------------$1.27B$2.02B$2.68B$3.98B$2.16B$2.76B$1.86B$1.97B$3.32B$3.30B$3.20B$2.98B$3.07B$3.41B$3.26B$3.26B$2.99B$3.10B
Avg Forecast$4.41B$4.31B$4.31B$4.02B$4.49B$4.40B$4.41B$4.14B$4.46B$4.27B$4.20B$3.28B$4.08B$3.48B$3.35B$2.98B$3.46B$2.67B$2.66B$2.71B$2.80B$2.71B$2.63B$3.24B$2.68B$2.60B$2.52B$2.91B$2.45B$2.29B
High Forecast$4.72B$4.61B$4.62B$4.30B$4.80B$4.70B$4.72B$4.45B$4.60B$4.27B$4.20B$3.93B$4.17B$4.19B$3.58B$3.57B$4.15B$2.67B$2.66B$3.25B$2.80B$2.71B$2.63B$3.89B$2.68B$2.60B$2.52B$3.49B$2.45B$2.29B
Low Forecast$4.20B$4.10B$4.11B$3.83B$4.27B$4.19B$4.20B$3.96B$4.31B$4.27B$4.20B$2.62B$4.01B$3.38B$3.19B$2.38B$2.76B$2.67B$2.66B$2.17B$2.80B$2.71B$2.63B$2.59B$2.68B$2.60B$2.52B$2.33B$2.45B$2.29B
Surprise %------------0.31%0.58%0.80%1.34%0.63%1.03%0.70%0.73%1.19%1.22%1.22%0.92%1.15%1.31%1.29%1.12%1.22%1.35%

9 analysts predict AMGN's average Quarter EBITDA for Mar 24 to be $3.28B, with a high of $3.93B and a low of $2.62B. This is 157.82% upper than Amgen's previous annual EBITDA (Dec 23) of $1.27B.

Amgen Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527168991018159101681099139910101099
Net Income------------$767.00M$1.73B$1.38B$2.84B$1.62B$2.14B$1.32B$1.48B$1.90B$1.88B$464.00M$1.65B$1.61B$2.02B$1.80B$1.82B$1.70B$1.97B
Avg Forecast$2.44B$2.96B$2.84B$2.58B$2.84B$2.94B$2.91B$2.61B$2.74B$2.86B$2.70B$1.72B$2.49B$2.53B$2.44B$1.56B$1.98B$2.42B$2.40B$1.42B$2.18B$2.32B$2.21B$1.79B$1.82B$2.12B$2.07B$1.63B$1.84B$1.91B
High Forecast$2.67B$3.23B$3.09B$2.82B$3.10B$3.20B$3.17B$2.83B$2.91B$2.90B$2.70B$2.06B$2.72B$2.67B$2.66B$1.88B$2.37B$2.42B$2.40B$1.71B$2.18B$2.32B$2.21B$2.15B$1.82B$2.12B$2.07B$1.95B$1.84B$1.91B
Low Forecast$2.29B$2.78B$2.66B$2.42B$2.66B$2.75B$2.72B$2.41B$2.58B$2.82B$2.70B$1.38B$2.32B$2.32B$2.28B$1.25B$1.58B$2.42B$2.40B$1.14B$2.18B$2.32B$2.21B$1.43B$1.82B$2.12B$2.07B$1.30B$1.84B$1.91B
Surprise %------------0.31%0.68%0.57%1.82%0.82%0.89%0.55%1.04%0.87%0.81%0.21%0.92%0.89%0.95%0.87%1.12%0.92%1.03%

Amgen's average Quarter net income forecast for Mar 24 is $1.72B, with a range of $1.38B to $2.06B. AMGN's average Quarter net income forecast represents a 124.33% increase compared to the company's last Quarter net income of $767.00M (Dec 23).

Amgen SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527168991018159101681099139910101099
SG&A------------$2.27B$1.35B$1.29B$1.26B$1.57B$1.29B$1.33B$1.23B$1.43B$1.30B$1.38B$1.25B$1.77B$1.35B$1.29B$1.32B$1.51B$1.22B
Avg Forecast$1.89B$1.85B$1.85B$1.73B$1.92B$1.89B$1.89B$1.77B$1.91B$1.83B$1.80B$1.43B$1.75B$1.49B$1.44B$1.30B$1.48B$1.41B$1.41B$1.18B$1.48B$1.44B$1.39B$1.36B$1.42B$1.38B$1.33B$1.17B$1.30B$1.21B
High Forecast$2.02B$1.98B$1.98B$1.85B$2.06B$2.02B$2.02B$1.91B$1.97B$1.83B$1.80B$1.72B$1.79B$1.79B$1.54B$1.56B$1.78B$1.41B$1.41B$1.42B$1.48B$1.44B$1.39B$1.63B$1.42B$1.38B$1.33B$1.41B$1.30B$1.21B
Low Forecast$1.80B$1.76B$1.76B$1.64B$1.83B$1.79B$1.80B$1.70B$1.85B$1.83B$1.80B$1.15B$1.72B$1.45B$1.37B$1.04B$1.19B$1.41B$1.41B$946.46M$1.48B$1.44B$1.39B$1.09B$1.42B$1.38B$1.33B$938.00M$1.30B$1.21B
Surprise %------------1.30%0.91%0.90%0.97%1.06%0.91%0.94%1.04%0.96%0.91%0.99%0.92%1.25%0.98%0.97%1.12%1.16%1.01%

Amgen's average Quarter SG&A projection for Mar 24 is $1.43B, based on 9 Wall Street analysts, with a range of $1.15B to $1.72B. The forecast indicates a -37.05% fall compared to AMGN last annual SG&A of $2.27B (Dec 23).

Amgen EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527168991018159101681099139910101099
EPS------------$1.43$3.23$2.58$5.32$3.02$4.01$2.46$2.69$3.38$3.32$0.81$2.85$2.78$3.45$3.07$3.09$2.87$3.29
Avg Forecast$4.51$5.46$5.23$4.77$5.24$5.42$5.36$4.81$5.06$5.27$4.98$3.88$4.59$4.67$4.49$3.85$4.10$4.47$4.43$4.10$4.04$4.29$4.09$4.05$3.36$3.93$3.82$3.74$3.41$3.53
High Forecast$4.92$5.96$5.71$5.20$5.71$5.91$5.85$5.23$5.37$5.35$4.99$3.88$5.02$4.92$4.90$4.20$4.33$4.47$4.43$4.10$4.04$4.29$4.09$4.05$3.36$3.93$3.82$3.74$3.41$3.53
Low Forecast$4.23$5.12$4.90$4.47$4.91$5.08$5.03$4.45$4.76$5.20$4.98$3.88$4.29$4.29$4.21$3.61$3.87$4.47$4.43$4.10$4.04$4.29$4.09$4.05$3.36$3.93$3.82$3.74$3.41$3.53
Surprise %------------0.31%0.69%0.57%1.38%0.74%0.90%0.55%0.66%0.84%0.77%0.20%0.70%0.83%0.88%0.80%0.83%0.84%0.93%

According to 9 Wall Street analysts, Amgen's projected average Quarter EPS for Mar 24 is $3.88, with a low estimate of $3.88 and a high estimate of $3.88. This represents a 171.26% increase compared to AMGN previous annual EPS of $1.43 (Dec 23).

Amgen Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BIIBBiogen$144.41$242.3367.81%Buy
MRKMerck$98.28$135.8338.21%Buy
LLYEli Lilly and$804.08$1.01K26.12%Buy
PFEPfizer$26.62$32.1720.85%Hold
ABBVAbbVie$175.26$211.2020.51%Buy
AMGNAmgen$281.68$338.2220.07%Buy
JNJJohnson & Johnson$151.15$178.7118.23%Buy
BMYBristol-Myers Squibb$59.05$61.003.30%Hold
GILDGilead Sciences$95.59$88.88-7.02%Buy

AMGN Forecast FAQ

Is Amgen a good buy?

Yes, according to 25 Wall Street analysts, Amgen (AMGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 15 'Buy' recommendations, accounting for 60.00% of AMGN's total ratings.

What is AMGN's price target?

Amgen (AMGN) average price target is $338.22 with a range of $215 to $405, implying a 20.07% from its last price of $281.68. The data is based on 25 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Amgen stock go up soon?

According to Wall Street analysts' prediction for AMGN stock, the company can go up by 20.07% (from the last price of $281.68 to the average price target of $338.22), up by 43.78% based on the highest stock price target, and down by -23.67% based on the lowest stock price target.

Can Amgen stock reach $400?

AMGN's highest twelve months analyst stock price target of $405 supports the claim that Amgen can reach $400 in the near future.

What are Amgen's analysts' financial forecasts?

Amgen's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $34.69B (high $37.16B, low $33.07B), average EBITDA is $17.44B (high $18.68B, low $16.62B), average net income is $11.29B (high $12.3B, low $10.55B), average SG&A $7.47B (high $8.01B, low $7.13B), and average EPS is $20.83 (high $22.7, low $19.47). AMGN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $33.95B (high $36.32B, low $32.31B), average EBITDA is $17.06B (high $18.25B, low $16.24B), average net income is $10.83B (high $11.81B, low $10.15B), average SG&A $7.31B (high $7.82B, low $6.96B), and average EPS is $19.97 (high $21.78, low $18.72).

Did the AMGN's actual financial results beat the analysts' financial forecasts?

Based on Amgen's last annual report (Dec 2023), the company's revenue was $28.19B, beating the average analysts forecast of $27.87B by 1.15%. Apple's EBITDA was $7.9B, missing the average prediction of $13.89B by -43.16%. The company's net income was $6.72B, missing the average estimation of $9.02B by -25.52%. Apple's SG&A was $6.18B, beating the average forecast of $5.98B by 3.32%. Lastly, the company's EPS was $12.56, missing the average prediction of $17.6 by -28.64%. In terms of the last quarterly report (Dec 2023), Amgen's revenue was $8.2B, beating the average analysts' forecast of $8.13B by 0.86%. The company's EBITDA was $1.27B, missing the average prediction of $4.08B by -68.88%. Amgen's net income was $767M, missing the average estimation of $2.49B by -69.18%. The company's SG&A was $2.27B, beating the average forecast of $1.75B by 29.88%. Lastly, the company's EPS was $1.43, missing the average prediction of $4.59 by -68.85%